MMP9 and Hepatic fibrosis: According to a study by Medeiros et al. [26], patients with chronic hepatitis C who were treated with direct-acting antiviral therapy had significantly lower levels of MMP-9/TIMP-1, suggesting that this complex may be a valuable biomarker for active fibrosis that can determine the extent of liver fibrosis in patients following viral clearance.